{
  "trial_id": "NCT03478982",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Subject is able to provide, personally signed, and dated informed consent to participate in the study or will have a legally authorized representative sign the informed consent on his or her behalf before completing any study related procedures.",
      "label": "met"
    },
    {
      "criterion": "Male or female \u2265 18 years of age.",
      "label": "met"
    },
    {
      "criterion": "Has an established diagnosis of focal or generalized epilepsy or focal and generalized epilepsy with a documented history of predictable seizure episodes that includes at least one of the following:",
      "label": "unknown"
    },
    {
      "criterion": "Generalized seizure episodes starting with a flurry of absence seizures or myoclonic seizures with a minimum duration of 5 minutes",
      "label": "not_met"
    },
    {
      "criterion": "Episodes of a prolonged focal seizure with a minimum duration of 3 minutes",
      "label": "unknown"
    },
    {
      "criterion": "Episodes of multiple (\u22652) seizures within a 2-hour time period",
      "label": "not_met"
    },
    {
      "criterion": "Prior to randomization, has experienced \u22654 seizure episodes with predictable pattern during the last 4 weeks (qualification period) and no more than one week without a predictable seizure episode before entry into the in-patient unit.",
      "label": "unknown"
    },
    {
      "criterion": "Female participants (if of child-bearing potential and sexually active) and male participants (if sexually active with a partner of child-bearing potential) who agree to use a medically acceptable and effective birth control method throughout the study and for 1 week following the end of the study.",
      "label": "met"
    },
    {
      "criterion": "Subject is able to comply by the requirements of the protocol, particularly the requirements and specific Institution policies during the in-clinic stay.",
      "label": "unknown"
    }
  ],
  "exclusion": [
    {
      "criterion": "History or diagnosis of non-epileptic seizures (e.g. metabolic or pseudo-seizures).",
      "label": "not_met"
    },
    {
      "criterion": "History of status epilepticus in the 6 months prior to Screening",
      "label": "unknown"
    },
    {
      "criterion": "Has a progressive neurological disorder such as brain tumor, demyelinating disease, or degenerative central nervous system (CNS) disease that is likely to progress in the next 3 months",
      "label": "not_met"
    },
    {
      "criterion": "Use of strong CYP 3A4 inhibitors; including azole antifungal agents (e.g., etoconazole, itraconazole), nefazodone, fluvoxamine, cimetidine, HIV protease inhibitors (e.g., ritonavir)",
      "label": "unknown"
    },
    {
      "criterion": "Has severe chronic cardio-respiratory disease",
      "label": "not_met"
    },
    {
      "criterion": "History of HIV-positivity.",
      "label": "not_met"
    },
    {
      "criterion": "Pregnant or breast-feeding.",
      "label": "unknown"
    }
  ],
  "notes": "Patient has a history of severe intellectual disability, CHF, and epilepsy. He has had seizures in the past but was able to control them with medication. He is currently experiencing facial twitching and generalized shaking, which required valium to cease seizure activity.",
  "_meta": {
    "topic_id": "9",
    "trial_id": "NCT03478982",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}